Charles Schwab
ELOX

Charles Schwab’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Charles Schwab’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,177
Closed -$731K – 3570
2021
Q2 		$731K Buy
9,177
+5,107
+125% +$426K ﹤0.01% 3041
2021
Q1 		$541K Hold
4,070
– – ﹤0.01% 3052
2020
Q4 		$648K Buy
4,070
+167
+4% +$20.4K ﹤0.01% 2904
2020
Q3 		$411K Sell
3,903
-4
-0.1% -$479 ﹤0.01% 2934
2020
Q2 		$474K Buy
3,907
+110
+3% +$12.5K ﹤0.01% 2852
2020
Q1 		$298K Sell
3,797
-26
-0.7% -$4.23K ﹤0.01% 2894
2019
Q4 		$1.13M Buy
3,823
+45
+1% +$9.07K ﹤0.01% 2558
2019
Q3 		$684K Buy
3,778
+549
+17% +$156K ﹤0.01% 2682
2019
Q2 		$1.29M Buy
3,229
+353
+12% +$149K ﹤0.01% 2496
2019
Q1 		$1.34M Sell
2,876
-75
-3% -$36.4K ﹤0.01% 2467
2018
Q4 		$1.42M Buy
2,951
+183
+7% +$101K ﹤0.01% 2432
2018
Q3 		$1.89M Buy
2,768
+24
+0.9% +$15.4K ﹤0.01% 2441
2018
Q2 		$1.87M Buy
+2,744
New +$1.78M ﹤0.01% 2400

Other funds holding ELOX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Charles Schwab's ELOX Position: Q3 2021 in Review

Charles Schwab sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q3 2021, closing a stake of 9,177 shares — an estimated $731K sold.

Charles Schwab first reported a position in ELOX in Q2 2018 and held it in 13 quarters. The position peaked at $1.89M in Q3 2018. 40 funds tracked by Wall St. Rank hold ELOX as of Q3 2021.

  • Charles Schwab reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 9,177 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $731K.
  • Charles Schwab first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
  • Charles Schwab's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $1.89M in Q3 2018.
  • 40 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.